Article
Oncology
Elizabeth R. Tucker, Irene Jimenez, Lindi Chen, Angela Bellini, Chiara Gorrini, Elizabeth Calton, Qiong Gao, Harvey Che, Evon Poon, Yann Jamin, Barbara Martins Da Costa, Karen Barker, Sumana Shrestha, J. Ciaran Hutchinson, Simran Dhariwal, Angharad Goodman, Elaine Del Nery, Pierre Gestraud, Jaydutt Bhalshankar, Yasmine Iddir, Elnaz Saberi-Ansari, Alexandra Saint-Charles, Birgit Geoerger, Maria Eugenia Marques Da Costa, Cecile Pierre-Eugene, Isabelle Janoueix-Lerosey, Didier Decaudin, Fariba Nemati, Angel M. Carcaboso, Didier Surdez, Olivier Delattre, Sally L. George, Louis Chesler, Deborah A. Tweddle, Gudrun Schleiermacher
Summary: ALK-activating mutations are present in approximately 10% of neuroblastomas and ALK amplifications in a further 1%-2% of cases. Lorlatinib, a third-generation ALK inhibitor, is being considered as a treatment for children with ALK-aberrant neuroblastoma. Resistance to single-agent treatment has been reported, and combination therapies with chemotherapy or MDM2 inhibitor are being explored to improve treatment efficacy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Tufia C. Haddad, Vera J. Suman, Antonino B. D'Assoro, Jodi M. Carter, Karthik V. Giridhar, Brendan P. McMenomy, Katelyn Santo, Erica L. Mayer, Meghan S. Karuturi, Aki Morikawa, P. Kelly Marcom, Claudine J. Isaacs, Sun Young Oh, Amy S. Clark, Ingrid A. Mayer, Khandan Keyomarsi, Timothy J. Hobday, Prema P. Peethambaram, Ciara C. O'Sullivan, Roberto A. Leon-Ferre, Minetta C. Liu, James N. Ingle, Matthew P. Goetz
Summary: This randomized clinical trial found that adding fulvestrant to treatment with alisertib did not increase objective tumor response rates (ORRs) or progression-free survival (PFS) in endocrine-resistant metastatic breast cancer (MBC).
Review
Oncology
Daniel An, Susana Banerjee, Jung-Min Lee
Summary: Ovarian cancer has a variety of treatment options, but achieving sustained benefit in the clinic remains challenging. Biomarker and genetic analysis can identify resistance and sensitivity pathways, providing potential for unique drug combinations.
CANCER TREATMENT REVIEWS
(2021)
Article
Biochemistry & Molecular Biology
Daniel Winardi, Pei-Yi Chu, Guan-Yu Chen, Ke Wang, Wei-Yu Hsu, Ching-Liang Hsieh, Yung-Hsiang Chen, Yang-Chang Wu, Juan-Cheng Yang
Summary: Fangchinoline, a natural compound, is identified as a potential adjuvant for ovarian cancer therapy by inhibiting Aurora A kinase activity and enhancing the efficacy of cisplatin treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Lichen Zhang, Deqiong Xie, Yonghua Lei, Aoli Na, Lei Zhu
Summary: Cobimetinib demonstrates potent anti-RCC activity and synergizes with standard-of-care drugs by suppressing the Raf/MEK/ERK pathway and enhancing the efficacy of other treatments.
Article
Pharmacology & Pharmacy
Jianbin Zhang, Yan Jiang, Ye Yu, Jiangping Li
Summary: This study evaluated the combination of TORC1/2 inhibitor sapanisertib and chemotherapy drug cisplatin for nasopharyngeal carcinoma (NPC) treatment. The results showed that sapanisertib effectively decreased NPC cell viability and proliferation, and acted synergistically with cisplatin to induce cell arrest and apoptosis. Sapanisertib had minimal effects on normal cells and also reduced NPC cell migration. These findings were evident in both in vitro and in vivo models.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Review
Oncology
Elizabeth R. Smith, Marilyn Huang, Matthew P. Schlumbrecht, Sophia H. L. George, Xiang-Xi Xu
Summary: Taxanes and CDK4/6 inhibitors are effective antimitotic drugs used in the treatment of solid tumors. Combining paclitaxel with CDK4/6 inhibitors shows potential as a therapeutic option for recurrent ovarian cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Huixia Li, Yifan Zheng, Peihang Xu, Zimu Li, Yukun Kuang, Xiaoqing Feng, Junhao He, Jia Li, Xiao Chen, Lihong Bai, Ke-Jing Tang
Summary: This study compared the risk of checkpoint inhibitor pneumonitis (CIP) between immune checkpoint inhibitor (ICI) monotherapy and combination with chemotherapy. The results showed that the combination of ICI plus chemotherapy was associated with higher pneumonitis toxicity compared to other drug regimens (including monotherapy). Therefore, caution should be exercised when using ICI plus chemotherapy in patients with potential risk factors for CIP.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Kent Thudium, Mark Selby, Julie A. Zorn, Gregory Rak, Xi -Tao Wang, Roderick Todd Bunch, Jason M. Hogan, Pavel Strop, Alan J. Korman
Summary: LAG-3 is an immunecheckpoint molecule inhibiting T-cell activity and antitumor immune responses through a different mechanism from PD-1 and CTLA-4. The combination of relatlimab and nivolumab shows enhanced antitumor activity in mouse models and is well-tolerated in toxicity studies in cynomolgus monkeys. RELATIVITY-047 phase II/III trial also demonstrates that relativlimab combined with nivolumab achieves superior progression-free survival in patients with unresectable or metastatic melanoma.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Oncology
Adria Bernat-Peguera, Macedonia Trigueros, Angelica Ferrando-Diez, Cristina Ibanez, Sara Bystrup, Anna Martinez-Cardus, Mireia Margeli, Eva Martinez-Balibrea
Summary: The study shows that the combination of CT-P6 and pertuzumab with chemotherapy is equivalent to reference trastuzumab (RTZ) in treating early breast cancer patients, with no differences in efficacy or adverse events. Additionally, the use of CT-P6-based treatments reduces costs.
Article
Oncology
Felix C. Saalfeld, Carina Wenzel, Petros Christopoulos, Sabine Merkelbach-Bruse, Timm M. Reissig, Silke Lassmann, Sebastian Thiel, Jan A. Stratmann, Ralf Marienfeld, Johannes Berger, Alexander Desuki, Janna-Lisa Velthaus, Diego Kauffmann-Guerrero, Albrecht Stenzinger, Sebastian Michels, Thomas Herold, Michael Kramer, Sylvia Herold, Amanda Tufman, Sonja Loges, Jurgen Alt, Maria Joosten, Gerlinde Schmidtke-Schrezenmeier, Martin Sebastian, Susann Stephan-Falkenau, Cornelius F. Waller, Marcel Wiesweg, Juergen Wolf, Michael Thomas, Daniela E. Aust, Martin Wermke
Summary: In this study, the efficacy of ICIs in HER2mu NSCLC patients was retrospectively evaluated, showing that ICI monotherapy and combination with chemotherapy had good efficacy. In treatment-naive patients, ICI in combination with chemotherapy showed a high overall response rate, progression-free survival, and overall survival rate at 1 year.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
David Howard, David James, Jezabel Garcia-Parra, Belen Pan-Castillo, Jenny Worthington, Nicole Williams, Zoe Coombes, Sophie Colleen Rees, Kerryn Lutchman-Singh, Lewis W. Francis, Paul Rees, Lavinia Margarit, R. Steven Conlan, Deyarina Gonzalez
Summary: Ovarian cancer is a deadly disease that is often diagnosed late, resulting in poor prognosis. Platinum-based therapies are commonly used, but resistance to these treatments is common, making prognosis even worse. This study aimed to evaluate the effectiveness of CDK inhibitors in platinum-resistant ovarian cancer models and their potential clinical utility. The results showed that the CDK inhibitor, dinaciclib, was highly effective in both cell lines and primary cells of ovarian cancer, even more so than cisplatin. Furthermore, resistance to cisplatin did not affect the sensitivity to dinaciclib, and the two drugs had an additive effect when used together. This suggests a potential role for pan-CDK inhibitors in the treatment of advanced and platinum-resistant ovarian cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Agriculture, Dairy & Animal Science
Yosra A. Helmy, Dipak Kathayat, Gary Closs Jr, Katie Galgozy, James R. Fuchs, Gireesh Rajashekara
Summary: Avian pathogenic E. coli (APEC) is a causative agent of colibacillosis, causing high mortality and morbidity in poultry and economic losses to the poultry industry worldwide. APEC can be transmitted to humans through contaminated poultry products. This study evaluated the efficacy of two small molecules, GI-7 and QSI-5, individually and in combination, in controlling APEC infections in chickens compared to the antibiotic SDM. The results showed promising effects of GI-7 and QSI-5 as potential antibiotic-independent approaches for controlling APEC infections in chickens.
Article
Oncology
T. M. Davidson, C. L. Lebreton, A. E. Wahner Hendricksen, H. J. Atkinson, M. C. Larson, A. L. Oberg, D. M. Provencher, J. A. Glaspy, B. Y. Karlan, D. J. Slamon, G. E. Konecny, I. L. Ray-Coquard
Summary: This study evaluated the efficacy and safety of ganitumab in patients with recurrent ovarian carcinoma. Ganitumab showed some treatment response in patients with CA125 progression and measurable disease, but further study of ganitumab as a single agent in unselected ovarian carcinoma patients is not supported.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Natalia Timofeeva, Mary L. Ayres, Natalia Baran, Janice M. Santiago-O'Farrill, Gamze Bildik, Zhen Lu, Marina Konopleva, Varsha Gandhi
Summary: CB-839 inhibits CLL cells by decreasing GLS-1 activity and glutathione synthesis. It shows synergy with venetoclax or AZD-5991, leading to increased apoptosis and inhibition of cell proliferation, but not with ibrutinib. The efficacy of CB-839 in CLL treatment is limited.
FRONTIERS IN ONCOLOGY
(2023)
